Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have been assigned a consensus rating of “Hold” from the five ratings firms that are presently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $13.75.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th.

Theravance Biopharma Price Performance

TBPH opened at $9.39 on Friday. The company has a market capitalization of $464.53 million, a PE ratio of -9.30 and a beta of 0.15. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $10.90. The business has a 50-day moving average of $9.34 and a 200-day moving average of $9.07.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.26). The business had revenue of $18.75 million for the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. On average, equities research analysts expect that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the transaction, the senior vice president now owns 309,565 shares of the company’s stock, valued at $2,786,085. The trade was a 1.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

Large investors have recently made changes to their positions in the business. Wellington Management Group LLP raised its stake in Theravance Biopharma by 3.7% during the 4th quarter. Wellington Management Group LLP now owns 198,491 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 7,162 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in Theravance Biopharma in the 4th quarter valued at approximately $353,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Theravance Biopharma by 27.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,039 shares of the biopharmaceutical company’s stock worth $1,412,000 after acquiring an additional 32,534 shares during the period. ProShare Advisors LLC acquired a new stake in shares of Theravance Biopharma during the 4th quarter worth approximately $119,000. Finally, Nuveen Asset Management LLC increased its position in shares of Theravance Biopharma by 10.9% during the fourth quarter. Nuveen Asset Management LLC now owns 495,727 shares of the biopharmaceutical company’s stock valued at $4,665,000 after purchasing an additional 48,635 shares during the period. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.